# India Diabetic Retinopathy Market > India Diabetic Retinopathy Market Research Report By Type (Non-Proliferative Diabetic Retinopathy (NPDR), Proliferative Diabetic Retinopathy (PDR)), By Treatment (Pharmacological Therapies, Laser Treatment, Surgery), and By End-user (Hospitals & Clinics, Ophthalmology Centers, Research Institutes) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.75% - **2024:** $ 488.4 Million - **2025:** $ 521.37 Million - **2035:** $ 1,002 Million - **Key Players:** Novartis (CH), Regeneron Pharmaceuticals (US), Roche (CH), Bayer (DE), Pfizer (US), Alcon (CH), Santen Pharmaceutical (JP), Hoya Corporation (JP) **Report ID:** MRFR/HC/48711-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/india-diabetic-retinopathy-market-50468 --- ## Market Summary ## **India Diabetic Retinopathy Market Overview** As per MRFR analysis, the India Diabetic Retinopathy Market Size was estimated at 431 (USD Million) in 2023. The India Diabetic Retinopathy Market is expected to grow from 452.5 (USD Million) in 2024 to 1,098 (USD Million) by 2035. The India Diabetic Retinopathy Market CAGR (growth rate) is expected to be around 8.392% during the forecast period (2025 - 2035). ### **Key India Diabetic Retinopathy Market Trends Highlighted** The market for diabetic retinopathy in India is expanding significantly due to a number of important considerations. A major factor propelling this market is the growing incidence of diabetes in India, where a sizable portion of the population suffers from the condition. A growing number of people are at risk for diabetic retinopathy since India has one of the highest rates of diabetes worldwide, according to the Indian Council of Medical Research. Additionally, as diabetic individuals' awareness of eye care has grown, proactive screening and diagnosis have increased, encouraging medical professionals to spend money on cutting-edge diagnostic tools. The integration of telemedicine services to improve access to eye care in rural places is one of the market's opportunities to be investigated. Innovative teleophthalmology projects can help alleviate healthcare access discrepancies between rural and urban areas by allowing patients to receive follow-up care and consultations without having to travel great distances. Furthermore, collaborations between the public and commercial sectors can make it simpler to obtain reasonably priced monitoring equipment and treatment alternatives, hence expanding treatment accessibility for larger populations. In India, recent trends show a growing trend towards the use of outpatient services and digital health platforms for the treatment of diabetic retinopathy. AI-based diagnostic tools are becoming more and more popular as healthcare technology develops since they aid in early diagnosis and improved patient care. Furthermore, a cultural change towards emphasising eye health among diabetics is demonstrated by the growth of patient support organisations and community awareness initiatives. These trends are reinforced by government programs and organisation education efforts emphasising the value of routine eye exams. All things considered, the Indian Diabetic Retinopathy Market shows encouraging trends in line with modernising healthcare and boosting patient involvement. Source Primary Research, Secondary Research, MRFR Database and Analyst Review ## **India Diabetic Retinopathy Market Drivers** ### **Increasing Prevalence of Diabetes** The rise in diabetes prevalence in India is a significant driver for the India Diabetic Retinopathy Market. According to the Indian Council of Medical Research, the number of adults living with diabetes in India has nearly doubled from 31.7 million in 2009 to about 62 million in 2019. This sharp increase correlates with an alarming rise in diabetic retinopathy cases, as approximately 25% of diabetics develop this complication. The Ministry of Health and Family Welfare has outlined that about 20% of patients with diabetes will ultimately develop some form of diabetic retinopathy, emphasizing the need for improved screening and treatment options. This growing patient base underlines the market's potential for growth, as established organizations like the All India Ophthalmological Society are actively promoting awareness and advanced treatment protocols. ### **Advancements in Treatment Technologies** Ongoing advancements in treatment technologies are propelling growth in the India Diabetic Retinopathy Market. Innovations such as anti-vascular endothelial growth factor (anti-VEGF) therapy and laser treatment options have improved patient outcomes significantly. The Indian Medical Association has reported that anti-VEGF treatments can reduce the risk of vision loss significantly, leading to increased adoption by healthcare providers. With more than 1,300 hospitals across the country equipped with the latest technology for retinal treatments, the incidence rate of effective interventions is expected to rise. This progress is primarily driven by established pharmaceutical companies that invest in Research and Development (R&D) for novel therapies specifically targeting diabetic eye diseases. ### **Government Initiatives and Awareness Programs** The Indian government is proactively addressing the diabetes epidemic through various initiatives and awareness programs, which are crucial for the India Diabetic Retinopathy Market. Government schemes such as the National Programme for Prevention and Control of Diabetes, Cardio Vascular Diseases and Stroke aim to educate the public on the importance of regular eye screenings for diabetes patients. The National Health Mission has also incorporated diabetic retinopathy screening into routine check-ups, aiming to reduce blindness caused by diabetes. According to reports, these national health campaigns have increased awareness by over 50% among diabetic patients regarding the need for eye examinations, thus expanding the market for diagnostic and treatment services in this sector. ### **Growing Geriatric Population** India's rapidly aging population is increasingly becoming a significant driver for the India Diabetic Retinopathy Market. According to the Ministry of Statistics and Programme Implementation, the geriatric population is projected to reach 173 million by 2026. This demographic is highly susceptible to chronic conditions, including diabetes and its complications. The Indian Geriatrics Society has reported that nearly 32% of elderly individuals suffer from diabetes, highlighting the urgency for specialized treatment and screening facilities. As the number of elderly individuals continues to rise, healthcare providers are expected to ramp up their services, leading to a greater demand for diabetic retinopathy management and thereby fostering market growth. ## **India Diabetic Retinopathy Market Segment Insights** ### **Diabetic Retinopathy Market Type Insights** The India Diabetic Retinopathy Market is characterized by its division into distinct types, mainly Non-Proliferative Diabetic Retinopathy (NPDR) and Proliferative Diabetic Retinopathy (PDR), which reflect the varying stages of this eye condition. NPDR, being the earlier stage of diabetic retinopathy, often presents without noticeable symptoms, leading to a large number of undiagnosed cases in the India population. This segment is significant as it serves as a critical marker for patient management and intervention strategies, particularly with the rising prevalence of diabetes in India. On the other hand, PDR represents a more advanced stage of the disease where retinal blood vessels begin to proliferate abnormally, posing a higher risk of vision loss. This segment is important as it often necessitates urgent medical intervention and treatment to prevent serious complications, emphasizing the need for awareness and timely diagnosis within the Indian healthcare framework. The demographic factors in India, particularly the increasing rates of obesity and sedentary lifestyles, contribute to an upward trend in diabetes-related eye diseases, thereby heightening the importance of effective screening and management strategies across both segments. The segmentation of the India Diabetic Retinopathy Market into NPDR and PDR thus not only aids in understanding the disease's progression but also informs healthcare providers on tailored treatment approaches essential to cater to the specific needs of Indian patients facing these conditions. Understanding this segmentation is critical for advancing the overall healthcare outcomes associated with diabetic retinopathy in India, given that timely care can significantly reduce the burden of severe vision loss within the population. The distinction between NPDR and PDR can help healthcare authorities implement more focused public health strategies and allocate resources more effectively, addressing the unique challenges associated with each stage of diabetic retinopathy. As diabetes prevalence continues to rise in India, the insights gained from examining these two types of diabetic retinopathy will be crucial for educating both patients and healthcare providers about the importance of regular eye examinations and the need for an integrated approach to diabetes management, ultimately playing a vital role in enhancing the quality of life for those affected. Source Primary Research, Secondary Research, MRFR Database and Analyst Review ### **Diabetic Retinopathy Market Treatment Insights** The Treatment segment of the India Diabetic Retinopathy Market is characterized by a diverse range of therapeutic options aimed at addressing the increasing prevalence of this condition among diabetic patients in the region. Pharmacological Therapies primarily encompass modern injectable medications that target the underlying disease pathways, providing crucial options for managing retinal complications. Laser Treatment plays a significant role, offering effective localized interventions to photocoagulate damaged retinal tissues and prevent further vision loss. Meanwhile, Surgery remains essential for advanced cases, where surgical procedures help to restore vision or prevent severe complications when other treatments are insufficient. The growing awareness of diabetes and its complications is driving demand for these treatment modalities, and the segment is poised for growth as healthcare access improves across India. With an increasing focus on Research and Development to innovate and enhance treatment efficacy, the Treatment segment is crucial in the Indian healthcare landscape as it strives to mitigate the impact of Diabetic Retinopathy on the population. Furthermore, the segment faces challenges such as cost barriers and the need for specialized training among healthcare professionals, yet it presents significant opportunities for healthcare providers and patients alike. ### **Diabetic Retinopathy Market End-user Insights** The India Diabetic Retinopathy Market is significantly driven by the End-user segment, which encompasses various healthcare facilities that play a vital role in diagnosing and treating this condition. Hospitals and Clinics are particularly crucial as they provide comprehensive care and have access to advanced technologies for detecting diabetic retinopathy at early stages. Many of these establishments have adopted innovative management technologies and treatment protocols, leading to improved patient outcomes. Ophthalmology Centers focus exclusively on eye care and are essential for specialized diagnosis and treatment, making them significant players in the management of diabetic retinopathy. With the growing prevalence of diabetes in India, research initiatives within Research Institutes are vital for advancing knowledge and developing better therapeutic strategies, creating a pipeline for innovative treatment solutions. This focus on research not only enhances clinical practices but also contributes to the overall growth of the India Diabetic Retinopathy Market by establishing new treatment paradigms and improving patient accessibility to care. The collaborative efforts across these end-user types underpin the health sector's response to the increasing burden of diabetic retinopathy in the country, highlighting the intersection of healthcare demand and medical innovation. ## **India Diabetic Retinopathy Market Key Players and Competitive Insights** The India Diabetic Retinopathy Market presents a dynamic and rapidly evolving landscape characterized by the increasing prevalence of diabetes and its associated complications. Diabetic retinopathy stands as one of the leading causes of blindness among adults in the country, driving demand for innovative treatment solutions and advancement in diagnostic technologies. The competitive insights within this market reveal a strong focus among various players on enhancing their product offerings, investing in research and development, and forming strategic partnerships. The emphasis on effective management of diabetic retinopathy through both pharmacological and non-pharmacological approaches has led to an intensified competitive atmosphere as companies strive to capture market share and meet the needs of healthcare providers and patients alike. Additionally, collaborations between pharmaceutical companies, healthcare institutions, and research organizations are becoming increasingly common, aiming to accelerate innovation and improve patient outcomes in the growing Indian market. Santen Pharmaceutical has a notable presence in the India Diabetic Retinopathy Market, emphasizing its commitment to providing high-quality ophthalmic solutions tailored to address diabetic eye disorders. The company's strategic focus on research and development has led to the introduction of specialized products that cater to the unique challenges faced by diabetic patients in India. With a customer-centric approach, Santen Pharmaceutical has established strong relationships with healthcare professionals, fostering trust and brand loyalty. Furthermore, their dedication to incorporating the latest advancements in surgical techniques and ophthalmic care positions them as a leader in the segment. The emphasis on education and awareness campaigns about diabetic retinopathy further strengthens their market presence, ensuring both patients and healthcare providers are informed about the importance of early detection and treatment. Bayer also plays a pivotal role in the India Diabetic Retinopathy Market, with a robust portfolio of innovative therapies aimed at effectively managing this condition. The company's flagship products include intravitreal injections that have shown significant efficacy in treating diabetic macular edema and other diabetic retinopathy-related complications. Bayer's extensive distribution network and strong relationships with ophthalmologists ensure that its products are readily accessible across various healthcare settings in India. Through strategic mergers and acquisitions, Bayer has enhanced its capabilities and broadened its market reach within the country. The company is investing in educational initiatives to raise awareness about diabetic retinopathy among patients and healthcare providers alike, contributing to a more informed population that understands the importance of timely intervention. Bayer's commitment to ongoing research and development in the field further solidifies its position as a key player in the Indian market, reflecting its strength and dedication to improving patient outcomes in diabetes-related eye health issues. ### **Key Companies in the India Diabetic Retinopathy Market Include** ## **India Diabetic Retinopathy Market Developments** The India Diabetic Retinopathy Market has seen significant developments recently, driven by rising diabetes prevalence and advancements in treatment modalities. In September 2023, Bayer launched a new retinal therapy aimed at improving outcomes for diabetic retinopathy patients. The Indian government has prioritized eye health, launching campaigns to enhance awareness and early detection of diabetic complications. Major pharmaceutical companies, including Santen Pharmaceutical, Novartis, and Roche, are increasing investments in Research and Development to innovate treatment solutions. In July 2023, Sun Pharmaceuticals announced partnerships to enhance its portfolio for diabetic retina treatment, reflecting a collaborative push within the industry. Notably, there have been no recent mergers or acquisitions reported among the key players in this market. Additionally, between 2021 and 2022, Dr. Reddy's Laboratories expanded its operations significantly to include a broader range of ophthalmic products, which bolstered its market presence. The growth in market valuation is fostering competition, pushing companies to enhance their product offerings and reach more patients. As awareness grows and technology improves, the landscape of the India Diabetic Retinopathy Market will likely continue evolving rapidly. ## **India Diabetic Retinopathy Market Segmentation Insights** ### **Diabetic Retinopathy Market Type Outlook** ### **Diabetic Retinopathy Market Treatment Outlook** ### **Diabetic Retinopathy Market End-user Outlook** ## Market Drivers ### Aging Population The aging population in India is a notable driver for the diabetic retinopathy market. As life expectancy increases, the prevalence of age-related diseases, including diabetes and its complications, is also rising. It is estimated that by 2030, the number of elderly individuals in India will reach approximately 300 million, many of whom are at risk for diabetic retinopathy. This demographic shift suggests a growing need for specialized eye care services and treatments, thereby expanding the diabetic retinopathy market. The healthcare system must adapt to cater to this aging population, which could lead to increased investments in eye care. ### Rising Healthcare Expenditure India's increasing healthcare expenditure is a significant factor influencing the diabetic retinopathy market. The government and private sectors are investing more in healthcare infrastructure, which includes eye care facilities. In recent years, healthcare spending has risen to about 3.5% of GDP, with a notable portion allocated to chronic disease management. This investment is expected to enhance access to advanced diagnostic and therapeutic options for diabetic retinopathy. As healthcare facilities improve, the diabetic retinopathy market is likely to experience growth due to better patient access to necessary treatments and technologies. ### Advancements in Treatment Options Recent advancements in treatment options for diabetic retinopathy are driving growth in the diabetic retinopathy market. Innovative therapies, such as anti-VEGF injections and laser treatments, have shown promising results in managing the disease. The introduction of these advanced treatment modalities has improved patient outcomes and reduced the risk of vision loss. Furthermore, the availability of these treatments in India is expanding, with more healthcare providers adopting them. This trend indicates a shift towards more effective management of diabetic retinopathy, which is likely to stimulate market growth as patients seek out these improved options. ### Government Support and Policy Initiatives Government support and policy initiatives aimed at combating diabetes and its complications are vital for the diabetic retinopathy market. The Indian government has launched various programs to promote diabetes awareness and improve access to healthcare services. Initiatives such as the National Programme for Prevention and Control of Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS) focus on early detection and management of diabetes-related complications. These policies are expected to enhance screening and treatment availability for diabetic retinopathy, thereby fostering growth in the market. As the government continues to prioritize eye health, the diabetic retinopathy market is likely to benefit from increased funding and resources. ### Increasing Awareness of Diabetic Retinopathy The growing awareness regarding diabetic retinopathy among the Indian population is a crucial driver for the diabetic retinopathy market. Educational campaigns by healthcare organizations and non-profits have significantly improved public knowledge about the disease. As a result, more individuals are seeking regular eye examinations, which is essential for early detection and treatment. Reports indicate that approximately 30% of individuals with diabetes in India are at risk of developing diabetic retinopathy, highlighting the need for proactive measures. This heightened awareness is likely to lead to increased demand for diagnostic tools and treatment options, thereby propelling the diabetic retinopathy market forward. ## Future Outlook The [Diabetic Retinopathy Market](https://www.marketresearchfuture.com/reports/diabetic-retinopathy-market-5792) is projected to grow at a 6.75% CAGR from 2025 to 2035, driven by increasing diabetes prevalence, technological advancements, and enhanced healthcare access. **New opportunities:** - Development of AI-driven diagnostic tools for early detection - Expansion of telemedicine services for remote patient monitoring - Investment in innovative drug delivery systems for treatment By 2035, the market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Non-Proliferative Diabetic Retinopathy (Largest) vs. Proliferative Diabetic Retinopathy (Fastest-Growing) In the India diabetic retinopathy market, Non-Proliferative Diabetic Retinopathy (NPDR) holds the largest market share, primarily due to its more prevalent nature among diabetic patients. This type accounts for the majority of diagnosed cases, as early detection and management lead to better outcomes. In contrast, Proliferative Diabetic Retinopathy (PDR), while representing a smaller share, is rapidly gaining attention as a critical area due to its severe implications and increasing incidence among patients. The growth of PDR is significant as healthcare providers focus on treatment options and innovative solutions for this advanced stage. The growth trends in this segment reflect the overall diabetes epidemic in the region, as the rising patient population directly correlates with the need for comprehensive eye care solutions. Key drivers for PDR's growth include advancements in diagnostic technologies, increased awareness of the condition, and enhanced treatment modalities available. Moreover, government initiatives focusing on diabetic care and access to ophthalmological services are playing a vital role in boosting the market for PDR. The emphasis on early intervention and new therapeutics is expected to drive further growth in this segment. Type: NPDR (Dominant) vs. PDR (Emerging) Non-Proliferative Diabetic Retinopathy (NPDR) is currently the dominant segment in the market, characterized by milder symptoms and a higher prevalence rate. It serves as the early stage of diabetic retinopathy, making it a focal point for screenings and preventive measures. Healthcare professionals prioritize NPDR due to its significant patient base and the efficacy of management strategies. In contrast, Proliferative Diabetic Retinopathy (PDR) is emerging as a critical segment, marked by advanced retinal changes that can lead to severe complications. The rising incidence of PDR is closely linked to the increasing prevalence of diabetes and the aging population. Efforts to improve diagnostic capabilities and treatment options, coupled with increasing public awareness, position PDR as a rapidly evolving segment in the India diabetic retinopathy market. ### By Treatment: Laser Treatment (Largest) vs. Pharmacological Therapies (Fastest-Growing) In the India diabetic retinopathy market, the treatment segment displays a diverse distribution of market share among its key players. Laser Treatment currently holds the largest share due to its established efficacy in treating advanced stages of the disease, while Pharmacological Therapies are rapidly gaining acceptance, demonstrating the fastest growth among treatment modalities. This shift is driven by increasing awareness of diabetic retinopathy and advancements in drug formulation. The growth trends in the treatment segment are significantly influenced by technological advancements and an increase in diabetic population. With rising incidences of diabetes, the demand for effective therapeutic options expands, thereby propelling the Pharmacological Therapies segment. Additionally, ongoing research and development activities are leading to new innovative therapies, which also contribute to the growing market share of this segment. Laser Treatment (Dominant) vs. Pharmacological Therapies (Emerging) Laser Treatment stands out as the dominant modality in the treatment segment of the India diabetic retinopathy market, recognized for its precision and effectiveness in immediately addressing vision-threatening conditions. Its widespread acceptance among healthcare providers is a result of its demonstrated success in managing retinal complications. In contrast, Pharmacological Therapies are classified as an emerging segment, benefitting from recent innovations aimed at preventing disease progression and improving patient compliance. These therapies, including intravitreal injections and oral medications, are becoming pivotal in tailored treatment plans, appealing to a broader demographic and showing substantial growth potential as more patients seek proactive management of their condition. ### By End User: Hospitals & Clinics (Largest) vs. Ophthalmology Centers (Fastest-Growing) In the India diabetic retinopathy market, the distribution of market share among the end-user segments shows that hospitals and clinics dominate with the largest share. This segment benefits from established patient volumes and integrated healthcare services, making it a go-to choice for diabetes-related eye care. On the other hand, ophthalmology centers are rapidly gaining traction, reflecting a strong growth trend driven by specialized services and patient-centric approaches, thus carving out a significant portion of the market. The growth trends in this segment are influenced by various factors, including the increasing prevalence of diabetes and its complications, heightened awareness of diabetic retinopathy, and advancements in diagnostic and therapeutic technologies. Hospitals and clinics are likely to continue thriving due to their comprehensive care offerings, while ophthalmology centers are buoyed by their focused expertise in eye care, appealing increasingly to patients seeking specialized services. Hospitals & Clinics (Dominant) vs. Ophthalmology Centers (Emerging) Hospitals and clinics stand as the dominant players within the end-user segment of the India diabetic retinopathy market. They are well-structured to offer extensive services, covering diagnosis, treatment, and follow-up for diabetic eye diseases. Their ability to integrate various healthcare services under one roof adds to their appeal among patients. Conversely, ophthalmology centers are emerging as notable contenders, specializing in eye care and benefiting from the latest technological advancements. Their focused approach allows them to deliver personalized services, thereby attracting a growing number of patients who seek dedicated eye care solutions. The competition between these two segments drives innovation and enhances the overall quality of care available to patients. ## Competitive Benchmarking The diabetic retinopathy market in India is characterized by a dynamic competitive landscape, driven by increasing prevalence rates and a growing awareness of eye health. Key players such as Novartis (CH), Regeneron Pharmaceuticals (US), and Bayer (DE) are actively shaping the market through strategic initiatives focused on innovation and regional expansion. Novartis (CH) has positioned itself as a leader in the development of novel therapies, while Regeneron Pharmaceuticals (US) emphasizes its commitment to research and development, particularly in the area of biologics. Bayer (DE) is leveraging its extensive distribution network to enhance accessibility to its products, thereby influencing the competitive environment significantly.The market structure appears moderately fragmented, with several players vying for market share. Companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. This strategy not only improves operational capabilities but also allows for quicker responses to market demands. The collective influence of these key players fosters a competitive atmosphere where innovation and strategic partnerships are paramount. In October Novartis (CH) announced a collaboration with a leading Indian healthcare provider to enhance patient access to its latest diabetic retinopathy treatment. This partnership is expected to facilitate the distribution of innovative therapies across rural and urban areas, thereby addressing the accessibility challenges faced by patients. Such strategic alliances are crucial for expanding market reach and improving patient outcomes. In September Regeneron Pharmaceuticals (US) launched a new clinical trial in India aimed at evaluating the efficacy of its latest drug for diabetic retinopathy. This move underscores the company's commitment to advancing treatment options tailored to the Indian population, potentially leading to improved therapeutic outcomes. The trial's results could significantly influence the company's market positioning and product offerings in the region. In August Bayer (DE) introduced a digital health platform designed to support diabetic retinopathy patients in managing their condition. This initiative reflects a broader trend towards digitalization in healthcare, where technology plays a pivotal role in patient engagement and treatment adherence. By integrating digital solutions, Bayer (DE) aims to enhance patient experiences and outcomes, thereby solidifying its competitive edge. As of November current trends in the diabetic retinopathy market indicate a shift towards digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, which will be essential for sustaining market leadership. ## Recent News & Developments The India Diabetic Retinopathy Market has seen significant developments recently, driven by rising diabetes prevalence and advancements in treatment modalities. In September 2023, Bayer launched a new retinal therapy aimed at improving outcomes for diabetic retinopathy patients. The Indian government has prioritized eye health, launching campaigns to enhance awareness and early detection of diabetic complications. Major pharmaceutical companies, including Santen Pharmaceutical, Novartis, and Roche, are increasing investments in Research and Development to innovate treatment solutions. In July 2023, Sun Pharmaceuticals announced partnerships to enhance its portfolio for diabetic retina treatment, reflecting a collaborative push within the industry. Notably, there have been no recent mergers or acquisitions reported among the key players in this market. Additionally, between 2021 and 2022, Dr. Reddy's Laboratories expanded its operations significantly to include a broader range of ophthalmic products, which bolstered its market presence. The growth in market valuation is fostering competition, pushing companies to enhance their product offerings and reach more patients. As awareness grows and technology improves, the landscape of the India Diabetic Retinopathy Market will likely continue evolving rapidly. ## Report Scope | MARKET SIZE 2024 | 488.4(USD Million) | | --- | --- | | MARKET SIZE 2025 | 521.37(USD Million) | | MARKET SIZE 2035 | 1002.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.75% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Novartis (CH), Regeneron Pharmaceuticals (US), Roche (CH), Bayer (DE), Pfizer (US), Alcon (CH), Santen Pharmaceutical (JP), Hoya Corporation (JP) | | Segments Covered | Type, Treatment, End User | | Key Market Opportunities | Advancements in telemedicine and AI-driven diagnostics enhance access to diabetic retinopathy care. | | Key Market Dynamics | Rising prevalence of diabetes drives demand for advanced diabetic retinopathy screening and treatment solutions in India. | | Countries Covered | India | ## Frequently Asked Questions **Q: What was the market valuation of the India diabetic retinopathy market in 2024?** A: The market valuation was $488.4 Million in 2024. **Q: What is the projected market valuation for the India diabetic retinopathy market by 2035?** A: The projected valuation for 2035 is $1002.0 Million. **Q: What is the expected CAGR for the India diabetic retinopathy market during the forecast period 2025 - 2035?** A: The expected CAGR during this period is 6.75%. **Q: Which segments contributed to the market valuation in 2024?** A: In 2024, Non-Proliferative Diabetic Retinopathy (NPDR) contributed $292.2 Million and Proliferative Diabetic Retinopathy (PDR) contributed $196.2 Million. **Q: What are the key treatment options available in the India diabetic retinopathy market?** A: Key treatment options include Pharmacological Therapies and Laser Treatment, each valued at $146.52 Million in 2024. **Q: How do the end-user segments perform in the India diabetic retinopathy market?** A: In 2024, Hospitals & Clinics generated $200.0 Million, while Ophthalmology Centers and Research Institutes contributed $150.0 Million and $138.4 Million, respectively. **Q: Who are the leading players in the India diabetic retinopathy market?** A: Key players include Novartis, Regeneron Pharmaceuticals, Roche, Bayer, Pfizer, Alcon, Santen Pharmaceutical, and Hoya Corporation. **Q: What is the projected growth trend for the Non-Proliferative Diabetic Retinopathy segment?** A: The Non-Proliferative Diabetic Retinopathy segment is expected to grow from $292.2 Million in 2024 to $609.6 Million by 2035. **Q: What is the anticipated performance of the Surgery treatment segment by 2035?** A: The Surgery treatment segment is projected to increase from $195.36 Million in 2024 to $391.76 Million by 2035. **Q: How does the market for Proliferative Diabetic Retinopathy compare to Non-Proliferative Diabetic Retinopathy?** A: Proliferative Diabetic Retinopathy is expected to grow from $196.2 Million in 2024 to $392.4 Million by 2035, indicating a robust market presence. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-diabetic-retinopathy-market-50468*